ArticleScientific reports2020
Interleukin-26 activates macrophages and facilitates killing of Mycobacterium tuberculosis.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Wnt/β-catenin signaling in hepatocellular carcinoma: a key player in resistance to targeted and immunotherapies.Carcinogenesis · 2026Review
- EliminateJournal of medical microbiology · 2026Article
- Integration of single-cell and bulk RNA sequencing reveals divergent T-cell immune circuits and a shared osteo-immune pathway in spinal tuberculosis and brucellar spondylitis.Frontiers in cellular and infection microbiology · 2026Article
- T cell-macrophage interactions in tuberculosis: What we've got here is failure to communicate.Journal of internal medicine · 2026Review
- Multifaceted Roles of IL-26 in Physiological and Pathological Conditions.International journal of molecular sciences · 2025Review
- Article
- Interleukin-10 family cytokines: key regulators and novel therapeutic targets for respiratory diseases.Inflammopharmacology · 2025Review
- Dynamics of Th1/Th17 responses and antimicrobial pathways in leprosy skin lesions.The Journal of clinical investigation · 2025Article
- Human neutrophils drive skin autoinflammation by releasing interleukin (IL)-26.The Journal of experimental medicine · 2024Article
- Interleukin-26 expression in tuberculosis disease and its regulatory effect in macrophage polarization and intracellular elimination ofFrontiers in cellular and infection microbiology · 2024Article
- CD30 co-stimulation drives differentiation of protective T cells during Mycobacterium tuberculosis infection.The Journal of experimental medicine · 2023Article
- Portable paper-based electrochemiluminescence test incorporating lateral-flow immunosensors for detection of interferon-γ levels.Frontiers in bioengineering and biotechnology · 2023Article
- Review
- Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis.Skin health and disease · 2022Review
- Interleukin-26 Expression in Inflammatory Bowel Disease and Its Immunoregulatory Effects on Macrophages.Frontiers in medicine · 2022Article
- The Kinocidin Interleukin-26 Shows Immediate Antimicrobial Effects Even to Multi-resistant Isolates.Frontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis-causing Mycobacterium tuberculosis (Mtb) is transmitted via airborne droplets followed by a primary infection of macrophages and dendritic cells. During the activation of host defence mechanisms also neutrophils and T helper 1 (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.